DENVER--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced results from a long-term study comparing SYMBICORT ® (budesonide/ formoterol fumarate dihydrate) Inhalation Aerosol 160/4.5 mcg with ...
For patients with COPD, the approved dosage of SYMBICORT is 160/4.5 mcg, 2 inhalations twice daily. The most common adverse events greater than or equal to 3% reported in COPD clinical trials included ...
SYMBICORT 80/4.5 and 160/4.5 were already approved in the US to treat asthma in patients 12 years and older. In September 2017, SYMBICORT160/4.5 was approved for reducing exacerbations in patients ...
The studies examined the efficacy of Symbicort pressurized metered dose inhaler (pMDI) 160/4.5mcg vs. formoterol 4.5mcg in reducing COPD exacerbations in adults with moderate to severe COPD. The FDA ...
Wilmington, DE – May 22, 2007 – New data demonstrated that the combination asthma therapy, SYMBICORT® (budesonide/formoterol fumarate dihydrate), led to ...
Wilmington, DE – February 24, 2007 – New data demonstrated the maintenance combination asthma therapy, SYMBICORT® (budesonide/formoterol fumarate dehydrate ...
WILMINGTON, Del.--(BUSINESS WIRE)--Results from a US comparative effectiveness study of two maintenance treatment options for patients with a history of chronic obstructive pulmonary disease (COPD) ...
SYMBICORT (Budesonide 160mcg, formoterol 4.5mcg) inhaler by AstraZeneca The FDA has approved Symbicort 160/4.5 micrograms (budesonide/formoterol fumarate dehydrate ...
WILMINGTON, Del., Sept. 10 Newly releasedresults from two previously published studies demonstrated patients receivingthe maintenance combination asthma therapy ...
LONDON (MarketWatch) -- Drugmaker AstraZeneca said Monday that the U.S. Food and Drug Administration has approved Symbicort 160/4.5 mcg for the twice daily maintenance treatment of airflow obstruction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback